Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project

John Gallacher, Frederic de Reydet de Vulpillieres, Billy Amzal, Zuzanna Angehrn, Christin Bexelius, Christophe Bintener, Jacoline C. Bouvy, Laura Campo, Carlos Díaz, Jean Georges, Alastair Gray, Antje Hottgenroth, Páll Jónsson, Brent Mittelstadt, Michele Potashman, Catherine Reed, Cathie Sudlow, Robin Thompson, Antje Tockhorn‐Heidenreich, Andrew Turner, Johan van der Lei, Pieter Jelle VisserJournal of Alzheimer s Disease 2018 · DOI

Abstract

ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
BibTeX
@article{gallacher2018challenges,
  author = {John Gallacher and Frederic de Reydet de Vulpillieres and Billy Amzal and Zuzanna Angehrn and Christin Bexelius and Christophe Bintener and Jacoline C. Bouvy and Laura Campo and Carlos Díaz and Jean Georges and Alastair Gray and Antje Hottgenroth and Páll Jónsson and Brent Mittelstadt and Michele Potashman and Catherine Reed and Cathie Sudlow and Robin Thompson and Antje Tockhorn‐Heidenreich and Andrew Turner and Johan van der Lei and Pieter Jelle Visser},
  title = {{Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project}},
  journal = {Journal of Alzheimer s Disease},
  year = {2018},
  doi = {10.3233/jad-180370},
}

Loading related content...

Figure